BLK
BlackRock, Inc.
BLK has slightly lower modeled downside risk, despite its lower overall score.
IVZ
Invesco Ltd.
IVZ has the edge over BLK overall, supported by stronger valuation and stronger modeled upside.
BLK Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| N/A | |
| N/A |
BLK's revenue and profitability are currently healthy. Free cash flow and net leverage aren't meaningful measures for financial services companies like BLK.
IVZ Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| N/A | |
| N/A |
IVZ's revenue is currently healthy, but its profitability is under pressure. Free cash flow and net leverage aren't meaningful measures for financial services companies like IVZ.
BLK PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 19x | $848 | -30% |
| Fair | 22x | $973 | -20% |
| Expensive | 26x | $1,149 | -5.5% |
| Current | 28x | $1,217 | — |
Historical ranges are pointers, not guarantees.
BLK's PE is in its expensive range at 28x.
IVZ PE Valuation
IVZ has no meaningful PE right now: it lost money over the past year.
BLK Forward outlook
There aren't enough analyst estimates for BLK to show an outlook.
IVZ Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Strong growth | |
| Growth | |
| Strongly improving | |
| Limited | |
| High |
Analysts expect earnings and revenue growth for IVZ, with profitability improving.
BLK Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $43.87 | +11% |
| Q2 2026 | $41.73 | -0.4% |
| Q1 2026 | $39.73 | -4.7% |
| Q4 2025 | $35.31 | -17% |
| Q3 2025 | $39.42 | -2.7% |
| Q2 2025 | $41.89 | +4% |
| Q1 2025 | $41.69 | +5.9% |
| Q4 2024 | $42.53 | +16% |
BLK has the stronger earnings trend. Trailing diluted EPS is up 11% for BLK versus IVZ down 176%.
IVZ Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.15 | — |
| Q1 2025 | $1.25 | +$1.99 |
| Q4 2024 | $1.18 | +$1.91 |
| Q3 2024 | -$0.91 | -169% |
| Q2 2024 | -$0.74 | -152% |
| Q1 2024 | -$0.74 | -154% |
| Q4 2023 | -$0.73 | -149% |
| Q3 2023 | $1.31 | -34% |
| Q2 2023 | $1.41 | -39% |
IVZ is still losing money, but less than at its worst: $0.69 per share over the past year, against $0.91 at its worst in late 2024.
BLK Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $7.8B | +19% |
| Q2 2026 | $7.1B | +31% |
| Q1 2026 | $6.7B | +27% |
| Q4 2025 | $7B | +23% |
| Q3 2025 | $6.5B | +25% |
| Q2 2025 | $5.4B | +13% |
| Q1 2025 | $5.3B | +12% |
| Q4 2024 | $5.7B | +23% |
BLK has the edge over IVZ on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 30% | 0 points |
| Q2 2026 | 35% | +2.8 points |
| Q1 2026 | 42% | +9.8 points |
| Q4 2025 | 24% | -13 points |
| Q3 2025 | 30% | -8.6 points |
| Q2 2025 | 32% | -5.5 points |
| Q1 2025 | 32% | -3.6 points |
| Q4 2024 | 37% | +2.3 points |
BLK has the edge over IVZ on profitability, with a higher operating margin.
IVZ Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.9B | +14% |
| Q2 2026 | $1.8B | +20% |
| Q1 2026 | $1.7B | +14% |
| Q4 2025 | $1.7B | +6.2% |
| Q3 2025 | $1.6B | +8.2% |
| Q2 2025 | $1.5B | +2.2% |
| Q1 2025 | $1.5B | +3.7% |
| Q4 2024 | $1.6B | +13% |
IVZ's revenue has grown year over year for 11 quarters in a row: $1.9B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 23% | +6.8 points |
| Q2 2026 | 20% | +5.8 points |
| Q1 2026 | 19% | +1 points |
| Q4 2025 | -86% | -106 points |
| Q3 2025 | 17% | +9.9 points |
| Q2 2025 | 14% | +0.2 points |
| Q1 2025 | 18% | +3.7 points |
| Q4 2024 | 20% | +96 points |
IVZ's operating margin was 23% last quarter, up 6.8 points from the same quarter a year ago.
BLK Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $2.6B | +95% |
| Q2 2026 | $1.1B | -12% |
| Q1 2026 | -$1.1B | +$120M |
| Q4 2025 | $2.1B | -15% |
| Q2 2025 | $1.3B | -6.1% |
| Q1 2025 | -$1.2B | -$734M |
| Q4 2024 | $2.5B | +35% |
| Q2 2024 | $1.4B | +47% |
BLK's free cash flow was $4.8B over the past year, up 22% from the year before. Free cash flow isn't a meaningful measure for financial services companies like BLK.
IVZ Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $442.8M | -24% |
| Q2 2026 | $703.7M | +33% |
| Q1 2026 | $198.4M | +$306.4M |
| Q4 2025 | $432.2M | +33% |
| Q3 2025 | $586.4M | +43% |
| Q2 2025 | $530.4M | +15% |
| Q1 2025 | -$108M | -$32.6M |
| Q4 2024 | $323.9M | -52% |
IVZ's free cash flow was $1.8B over the past year, up 33% from the year before. Free cash flow isn't a meaningful measure for financial services companies like IVZ.
BLK Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.1% | -148K shares |
| 1 year | -0.4% | -677K shares |
| 3 years | +9.3% | +14M shares |
| 5 years | +6.2% | +9.6M shares |
| Available history | +4.4% | +7M shares |
BLK has 165M diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q2 2025 | $396M |
| Q1 2025 | $657M |
| Q4 2024 | $386M |
| Q2 2024 | $519M |
| Q1 2024 | $634M |
| Q4 2023 | $384M |
| Q3 2023 | $396M |
| Q2 2023 | $383M |
IVZ Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.4% | -1.9M shares |
| 1 year | -0.5% | -2.1M shares |
| 3 years | -1.4% | -6.3M shares |
| 5 years | -2.9% | -13.7M shares |
| Available history | +2.7% | +12M shares |
IVZ has the edge over BLK on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $75M |
| Q2 2026 | $50.4M |
| Q1 2026 | $69.2M |
| Q4 2025 | $25.8M |
| Q3 2025 | $29.2M |
| Q2 2025 | $25.5M |
| Q1 2025 | $43.1M |
| Q4 2024 | $26M |
IVZ spent $220M buying back its own shares over the past year, up 78% from the year before.
BLK Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.0x | Net Cash |
| Q2 2026 | 0.2x | Very low |
| Q1 2026 | 0.3x | Very low |
| Q4 2025 | 0.2x | Very low |
| Q3 2025 | 0.3x | Very low |
| Q2 2024 | 0.2x | Very low |
| Q1 2024 | 0.3x | Very low |
| Q4 2023 | 0.1x | Very low |
BLK has more cash than debt. Net leverage isn't a meaningful measure for financial services companies like BLK.
IVZ Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | 0.5x | Very low |
| Q2 2025 | 0.9x | Very low |
| Q1 2025 | 0.1x | Very low |
| Q4 2024 | -0.1x | Net Cash |
| Q3 2023 | 0.2x | Very low |
| Q2 2023 | 0.4x | Very low |
| Q1 2023 | 0.5x | Very low |
| Q4 2022 | 0.0x | Very low |
IVZ's net debt is less than a year of its operating earnings (EBITDA). Net leverage isn't a meaningful measure for financial services companies like IVZ.
BLK Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 64.5 | Neutral |
| Stochastic | 79.0 | Neutral |
BLK's weekly RSI is 64 (neutral) and its Stochastic is 79 (neutral).
IVZ Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 48.2 | Neutral |
| Stochastic | 11.7 | Oversold |
IVZ's weekly RSI is 48 (neutral) and its Stochastic is 12 (oversold).
BLK PE vs Financial Services Sector
| Metric | BLK | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 13x | 113% above |
| PE % | 97 | 63 | 34 pts above |
BLK is trading at 28x earnings, a 113% premium to the Financial Services sector's median of 13x.
IVZ PE vs Financial Services Sector
| Metric | IVZ | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 13x | — |
IVZ has no meaningful PE right now: it lost money over the past year.
BLK Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,128.0 | 7.9% above |
| 20 week MA | $1,108.9 | 9.7% above |
| 50 week MA | $1,071.6 | 14% above |
| 100 week MA | $1,051.1 | 16% above |
| 200 week MA | $914.1 | 33% above |
BLK has the edge over IVZ on trend strength, trading above more of its moving averages.
IVZ Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $28.8 | 1.2% below |
| 20 week MA | $30.0 | 5.2% below |
| 50 week MA | $27.8 | 2.3% above |
| 100 week MA | $23.2 | 23% above |
| 200 week MA | $19.7 | 45% above |
IVZ has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 45% above its 200-week average.
BLK Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $503.0 | $707.2 | +41% |
| 2021 | $707.2 | $913.9 | +29% |
| 2022 | $913.9 | $703.9 | -23% |
| 2023 | $703.9 | $811.8 | +15% |
| 2024 | $811.8 | $1,044.2 | +29% |
| 2025 | $1,044.2 | $1,088.1 | +4.2% |
| 2026 YTD | $1,088.1 | $1,216.6 | +12% |
BLK has the edge over IVZ on returns for 2026, with the stronger performance.
IVZ Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $17.8 | $17.6 | -1.2% |
| 2021 | $17.6 | $23.3 | +33% |
| 2022 | $23.3 | $18.4 | -21% |
| 2023 | $18.4 | $17.8 | -2.9% |
| 2024 | $17.8 | $17.7 | -0.9% |
| 2025 | $17.7 | $27.0 | +52% |
| 2026 YTD | $27.0 | $28.5 | +5.6% |
IVZ has finished lower in four of the last six years. It's up 5.6% so far in 2026.